JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

JPMorgan Chase & Co. lifted its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 29.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,964 shares of the company’s stock after purchasing an additional 4,512 shares during the period. JPMorgan Chase & Co.’s holdings in Stoke Therapeutics were worth $220,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the fourth quarter worth $63,000. Teacher Retirement System of Texas bought a new position in shares of Stoke Therapeutics in the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth $124,000. EntryPoint Capital LLC purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth $353,000. Finally, Rhumbline Advisers grew its stake in Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after purchasing an additional 2,787 shares during the last quarter.

Analyst Ratings Changes

Several research firms have commented on STOK. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. HC Wainwright restated a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $24.67.

Stoke Therapeutics Trading Down 2.4 %

Shares of Stoke Therapeutics stock opened at $9.63 on Friday. The firm’s 50 day simple moving average is $7.90 and its two-hundred day simple moving average is $10.18. The firm has a market capitalization of $525.77 million, a price-to-earnings ratio of -4.59 and a beta of 1.20. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,532 shares of company stock valued at $143,332. Company insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.